Unraveling microprotein biology with an evolutionary-immunological framework
Project Number5R01AT012826-02
Former Number1R01OD035155-01
Contact PI/Project LeaderCARVUNIS, ANNE-RUXANDRA Other PIs
Awardee OrganizationUNIVERSITY OF PITTSBURGH AT PITTSBURGH
Description
Abstract Text
Recent technological advances have revealed the existence of thousands of microproteins (<100 amino acids)
missing from genome annotations, but little is known about their function. The physiological relevance of this
‘biological dark matter’ is one of the biggest outstanding mysteries in modern biology. Compared to canonical
proteins, microproteins evolve at a strikingly fast pace. They frequently appear de novo and rapidly disappear
through disabling mutations, overwhelmingly exhibiting evolutionarily novel sequences found in only one
species or lineage. The lack of evolutionary conservation renders homology-based approaches for functional
prediction powerless and raises the concern that many microproteins might not be functional. The selective
pressures driving the rapid evolution of microproteins are largely unknown. In mammals, one of the most well-
characterized determinants of protein evolution is the immune system. Novel sequences are positively selected
when they mediate functional innovations that enable cells to mount effective innate immune responses to fast
evolving pathogens. Novel sequences are negatively selected when are recognized as foreign by the adaptive
immune system. We reasoned that the tremendous strength of these immune selective pressures is likely to
drive the rapid evolution of microproteins. We therefore propose that the immune system is a critical
determinant of microprotein function and evolution. We hypothesize that novel microproteins can only evolve to
perform cell-intrinsic functions if they are recognized as ‘self’, and thereby tolerated, by the adaptive immune
system. The lineage-specific sequences of these novel but tolerated microproteins would provide a vital
arsenal against rapidly evolving pathogens. Conversely, novel microproteins that are recognized as ‘non-self’
would induce auto-immune responses and rapidly disappear over evolutionary time.
In this project, we will test the above hypotheses at a proteome-wide level using well established
cellular and animal model systems. We will combine: 1) Integrative ribosome profiling to generate a reference
microprotein expression atlas in mice; 2) T cell antigen discovery approaches and mouse models of
autoimmunity to assess the immunogenic potential of microproteins; 3) Genome-scale gain- and loss-of-
function genetic screens to determine cell-intrinsic, innate immune roles of microproteins; and 4)
Computational evolutionary genomics to reconstruct the evolutionary history, and estimate the strength of
selective pressures acting on microproteins. Our proposed work is centered on mouse models and murine
cells due to availability of specific genetic knock-out models and large quantities of matched tissues, plethora
of published transcriptome and translatome datasets, and ability to perform experiments in a controlled,
homogeneous setting with defined immune genetics. Together, these approaches will illuminate the
evolutionary and immunological principles that govern the large, but uncharacterized universe of microproteins
and identify microproteins with innate immune function or autoimmune potential.
Public Health Relevance Statement
PROJECT NARRATIVE
A major function of the immune system is to discriminate between self and non-self, but
occasionally immune cells mistake self-molecules for non-self and attack the body’s own
healthy cells, triggering auto-immune diseases. In most cases, the identity of the self-molecules
that trigger auto-immunity is unknown. This project will explore the auto-immune potential of an
entirely uncharted pool of self-molecules, called ‘microproteins’, with the long-term goals to
unlock novel therapeutic strategies for autoimmune diseases and understand the forces that
govern microprotein biology.
National Center for Complementary and Integrative Health
CFDA Code
310
DUNS Number
004514360
UEI
MKAGLD59JRL1
Project Start Date
08-September-2023
Project End Date
31-August-2028
Budget Start Date
01-September-2024
Budget End Date
31-August-2025
Project Funding Information for 2024
Total Funding
$1,485,481
Direct Costs
$1,092,242
Indirect Costs
$393,239
Year
Funding IC
FY Total Cost by IC
2024
NIH Office of the Director
$1,485,481
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AT012826-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AT012826-02
Patents
No Patents information available for 5R01AT012826-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AT012826-02
Clinical Studies
No Clinical Studies information available for 5R01AT012826-02
News and More
Related News Releases
No news release information available for 5R01AT012826-02
History
No Historical information available for 5R01AT012826-02
Similar Projects
No Similar Projects information available for 5R01AT012826-02